Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortization of Deferred Charges (2020 - 2024)

Seres Therapeutics' Amortization of Deferred Charges history spans 5 years, with the latest figure at $463000.0 for Q3 2024.

  • For Q3 2024, Amortization of Deferred Charges rose 17.81% year-over-year to $463000.0; the TTM value through Jun 2025 reached $463000.0, down 73.57%, while the annual FY2024 figure was $1.4 million, 24.06% up from the prior year.
  • Amortization of Deferred Charges for Q3 2024 was $463000.0 at Seres Therapeutics, down from $485000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.2 million in Q4 2021 and bottomed at $118000.0 in Q1 2021.
  • The 5-year median for Amortization of Deferred Charges is $208500.0 (2020), against an average of $375312.5.
  • The largest annual shift saw Amortization of Deferred Charges soared 872.07% in 2021 before it tumbled 92.96% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $222000.0 in 2020, then skyrocketed by 872.07% to $2.2 million in 2021, then crashed by 92.96% to $152000.0 in 2022, then surged by 169.08% to $409000.0 in 2023, then grew by 13.2% to $463000.0 in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Amortization of Deferred Charges are $463000.0 (Q3 2024), $485000.0 (Q2 2024), and $465000.0 (Q1 2024).